Immunome
Stock Forecast, Prediction & Price Target
Immunome Financial Estimates
Immunome Revenue Estimates
Immunome EBITDA Estimates
Immunome Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $14.01M 0% | Avg: $703.32K Low: $260.86K High: $1.51M avg. -94.98% | Avg: $13.83M Low: $5.13M High: $29.88M avg. 1867.38% | Avg: $68.38M Low: $25.36M High: $147.69M avg. 394.19% | Avg: $167.39M Low: $62.08M High: $361.53M avg. 144.79% |
Net Income
% change YoY
| $-24.46M N/A | $-37.51M -53.30% | $-106.80M -184.71% | Avg: $-161.43M Low: $-76.99M High: $-38.15M avg. -51.15% | Avg: $-214.91M Low: $-94.25M High: $-48.22M avg. -33.12% | Avg: $-57.38M Low: $-143.91M High: $-10.45M avg. 73.29% | Avg: $-21.97M Low: $-55.11M High: $-4.00M avg. 61.70% |
EBITDA
% change YoY
| $-24.70M N/A | $-36.27M -46.83% | $-28.27M 22.05% | Avg: $421.99K Low: $156.51K High: $911.42K avg. 101.49% | Avg: $8.30M Low: $3.07M High: $17.93M avg. 1867.38% | Avg: $41.02M Low: $15.21M High: $88.61M avg. 394.19% | Avg: $100.43M Low: $37.25M High: $216.92M avg. 144.79% |
EPS
% change YoY
| -$2.12 N/A | -$3.09 -45.75% | -$5.38 -74.11% | Avg: -$2.64 Low: -$3.88 High: -$1.92 avg. 51.01% | Avg: -$3.34 Low: -$4.75 High: -$2.43 avg. -26.58% | Avg: -$2.89 Low: -$7.25 High: -$0.53 avg. 13.30% | Avg: -$1.11 Low: -$2.78 High: -$0.2 avg. 61.70% |
Operating Expenses
% change YoY
| $25.20M N/A | $36.90M 46.40% | $122.82M 232.83% | Avg: $759.90K Low: $281.84K High: $1.64M avg. -99.38% | Avg: $14.95M Low: $5.54M High: $32.28M avg. 1867.38% | Avg: $73.88M Low: $27.40M High: $159.57M avg. 394.19% | Avg: $180.85M Low: $67.08M High: $390.62M avg. 144.79% |
FAQ
What is Immunome stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 12.68% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -76.99M, average is -161.43M and high is -38.15M.
What is Immunome stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 577.84% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $260.86K, average is $703.32K and high is $1.51M.
What is Immunome stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 24.86% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$3.88, average is -$2.64 and high is $-1.92.
What is the best performing analyst?
In the last twelve months analysts have been covering Immunome stock. The most successful analyst is Michael Schmidt.